Perkinelmer Inc (PKI): Robert F Friel , President and CEO of Perkinelmer Inc sold 10,685 shares on May 11, 2016. The Insider selling transaction was reported by the company on May 12, 2016 to the Securities and Exchange Commission. The shares were sold at $55.01 per share for a total value of $587,781.88 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 12, 2016, Vicki L Sato (director) sold 12,586 shares at $54.27 per share price.On May 9, 2016, Robert F Friel (President and CEO) sold 4,116 shares at $55.00 per share price.Also, On Apr 19, 2016, Daniel R Tereau (officer ) sold 2,158 shares at $50.79 per share price.On Mar 23, 2016, James Corbett (officer ) sold 1,723 shares at $48.74 per share price.
PerkinElmer: On Tuesday, May 10, 2016 heightened volatility was witnessed in PerkinElmer which led to swings in the share price. The shares opened for trading at $54.06 and hit $54.95 on the upside , eventually ending the session at $54.91, with a gain of 1.76% or 0.95 points. The heightened volatility saw the trading volume jump to 7,03,165 shares. The 52-week high of the share price is $55 and the company has a market cap of $6,029 M . The 52-week low of the share price is at $39.5.
Company has been under the radar of several Street Analysts.PerkinElmer is Reiterated by Stifel to Buy and the brokerage firm has raised the Price Target to $ 59 from a previous price target of $51 .The Rating was issued on May 6, 2016.PerkinElmer is Reiterated by Mizuho to Buy and the brokerage firm has raised the Price Target to $ 56 from a previous price target of $52 .The Rating was issued on May 6, 2016.PerkinElmer is Downgraded by BofA/Merrill to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Apr 5, 2016.PerkinElmer is Initiated by Barclays to Underweight and the brokerage firm has set the Price Target at $46. The Rating was issued on Mar 1, 2016.
PerkinElmer Inc. is a provider of products services and solutions to the diagnostics research environmental industrial and laboratory services markets. The Company operates its business in two segments: Human Health and Environmental Health. The Companys Human Health segment concentrates on developing diagnostics tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of new therapies. The Companys Environmental Health segment provides products services and solutions to facilitate the creation of safer food and consumer products more secure surroundings and efficient energy resources. The Company markets its products and services in more than 150 countries.